Ryan Swenerton, Ph.D. Email & Phone Number

Austin, Texas, US

Austin, Texas, US

• Leading research efforts creating innovative nucleic acid-based technologies linking liquid biopsy and next-generation sequencing for oncology, prenatal diagnostics, and organ transplantation.
• Signatera: Transforming the management of cancer with truly personalized testing. Signatera is the first ultra-sensitive custom circulating tumor DNA test for molecular monitoring of recurrence, minimal residual.
• Panorama: Non-invasively screening for fetal aneuploidies of chromosomes 21, 18, 13 and X and micro deletions using massively multiplexed PCR (https://www.natera.com/panorama-test).
• Prospera: Non-invasive organ transplant test for assessing allograft health with superior analytical and clinical performance (https://www.natera.com/prospera).

Austin, Texas, US

Austin, Texas, US

Austin, Texas, US

Austin, Texas, US

Purigen Biosystems, Inc. is an early stage biotechnology start-up company.

Shelton, CT, US

• Life Sciences & TechnologyAssay Development: Microfluidics R&D
• Led new product development (kits, reagents, and automation) on the PerkinElmer LabChip MultiDx (CE-IVD-marked), LabChip GXI/II and GX Touch (automated electrophoresis), LabChip XT (fractionation), imaging, and liquid.
• Designed new assays and functionalities for these platforms to strategically strengthen PerkinElmer’s product portfolio for next-gen sequencing, biotherapeutics, epigenetics, molecular diagnostics, and biomarker and.
• Worked in and led cross-functional teams comprised of biologists, chemists, software and mechanical engineers, and sales/marketing personnel.
• Collaborated with key customers to design and optimize products in the PerkinElmer pipeline and provided support and training for newly launched products.

San Francisco, California, US

• Sandler Center for Drug DiscoveryIdentification and Screening of Antimicrobial Drugs
• Coordinated research between UCSF and Stanford University laboratories to repurpose FDA-approved compounds for use against neglected infectious diseases.
• Designed and developed research strategies for drug selection and evaluation using in silico, in vitro, cell-based, and in vivo screens.

San Francisco, California, US

• Principal Investigator: James McKerrow, M.D., Ph.D.Biochemical and Functional Characterization of Serine Proteases in Leishmania spp.
• Identified and isolated two novel virulence factors of protozoan parasites in the Leishmania genus.
• Developed two in vitro drug screens for compounds with leishmanicidal activity. Identified several compounds taken into the animal infection model.
• Presented findings at multiple international meetings. Produced two first-author research articles based on the results of these studies. Co-authored a textbook chapter and a scientific review article on proteases in.

San Francisco, CA, US

• Part-time faculty member in the Biology Department.
• Lecturer and course organizer for second-semester General Biology (100 undergraduate students).
• Employed state-of-the-art teaching technologies including CPS Clickers and Blackboard Learning System.

Rockville, Maryland, US

• High-Throughput Proteomics Assay Development
• Created two assays to detect tyrosine kinase activity or ubiquitylation from in vitro translated proteins using IGEN’s proprietary electro-chemiluminescent screening technology.
• Successfully screened IGEN’s libraries with these assays, providing proof-of-principle for this novel technology and screening platform.
• Formatted these assays for high-throughput screening with robotics and wrote operating procedures for the high-throughput screens.

Boston, MA, US

• Principal Investigator: Ruth Ruprecht, M.D., Ph.D.Biomarker Detection and Molecular Diagnostics for HIV and SIV Infections
• Created highly sensitive RT-PCR assays for determining the SIV viral load in rhesus macaques as well as for a panel of simian cytokine and B-chemokine mRNAs.
• Used these assays to track viral load, cytokine, and chemokine production during different stages of SIV infection. Two papers were published based on this work.

Cambridge, MA, US

• Principal Investigator: Graham Walker, Ph.D.E. coli SOS Response to DNA Damage
• Identified motifs of the UmuD protein necessary for functional SOS Response by generating truncations and missense mutations in the N-terminal end of UmuD using site-directed mutagenesis.
• Transfected the mutant umuD genes into umuD deficient E. coli and tested for susceptibility to mutagenesis by UV light. Demonstrated that several of the bacterial strains containing specific N-terminal truncations of.

Davis, California, US

• Principal Investigator: Bruce Hammock, Ph.D.Adult Respiratory Distress Syndrome (ARDS): Toxicity of Leukotoxin
• Characterized the structural features required for epoxy fatty acid toxicity in order to understand more about the relationship between leukotoxin and ARDS.
• Produced a panel of leukotoxin analogues using organic synthesis. Compared the toxicity of these epoxy fatty acids to their corresponding diols. Determined that leukotoxin toxicity may be due to its metabolization into.

Phd, Biomedical Sciences, Microbial Pathogenesis

Sb, Biology, Bioengineering And Environmental Health

High School Diploma--Valedictorian